Hemispherx Biopharma, Inc.
(NYSE Amex Equities : HEB)

( )
HEB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading HEB News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.66%68.831.0%$926.55m
AMGNAmgen Inc.
-0.31%172.610.8%$655.47m
BIIBBiogen Inc.
0.25%287.630.9%$526.94m
CELGCelgene Corporation
-0.14%119.271.0%$480.99m
REGNRegeneron Pharmaceuticals, Inc.
-0.37%370.221.9%$341.26m
ALXNAlexion Pharmaceuticals, Inc.
0.72%130.832.0%$299.85m
TSROTESARO, Inc.
-0.17%189.9415.3%$195.91m
INCYIncyte Corporation
-0.82%121.362.3%$163.54m
ILMNIllumina, Inc.
0.09%162.303.9%$144.45m
VRTXVertex Pharmaceuticals Incorporated
-0.88%85.792.6%$139.38m
EXELExelixis, Inc.
-2.12%22.625.5%$127.92m
CLVSClovis Oncology, Inc.
-2.86%61.1916.4%$127.65m
AAgilent Technologies, Inc.
-0.04%51.331.7%$116.31m
ACADACADIA Pharmaceuticals Inc.
-0.15%39.1419.0%$93.49m
BMRNBioMarin Pharmaceutical Inc.
-0.50%89.794.0%$90.43m

Company Profile

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.